- Email: [email protected]
5th International Workshop on IGF-Binding Proteins - Meeting Programme
Growth Hormone & IGF Research 13 (2003) 193–202 www.elsevier.com/locate/ghir
Abstracts of the 5th International Workshop on IGF-Binding Proteins August 7–10, 2003 Karolinska Institutet Stockholm, Sweden Scientific Organising Committee Moira Lewitt, Chair (Sweden) Kerstin Hall, Co-Chair (Sweden) Kerstin Brismar, Co-Chair (Sweden) Peter Bang (Sweden) Ross Clark (New Zealand) David Clemmons (USA) Pinchas Cohen (USA) Allan Flyvbjerg (Denmark) Linda Giudice (USA) Yukihiro Hasegawa (Japan) Janet Martin (Australia) Philippe Monget (France) Liam Murphy (Canada) Claire Perks (UK) Zee Upton (Australia)
doi:10.1016/S1096-6374(03)00037-6
Major Sponsor Novo Nordisk Foundation Other Sponsors The Wenner-Gren Foundation Insmed Inc. Diagnostic Systems Laboratories, Inc. Biovitrum AB Pharmacia Corporation, Sweden Novo Nordisk Scandinavia AB Glaxo SmithKline, Sweden
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Meeting Plan Thursday August 7, 2003 Registration 13.00–17.30 Session 1: IGFBPs and the Somatomedin Hypothesis 2003 15.40–17.30 Chairs: 15.40–16.00
Kerstin Brismar, Kerstin Hall and Moira Lewitt, Sweden Introduction
Invited Speakers: 16.00–16.30 Victor Han, The University of Western Ontario, Canada S1 Regional expression of the IGF system during development: Evidence for autocrine/ paracrine actions of IGFBPs 16.30–17.00 Jan Frystyk, Aarhus University Hospital, Denmark S2 What are ‘‘free IGFs’’? 17.00–17.30 Derek LeRoith, NIH, Bethesda, USA S3 What is the role of circulating IGF-I? Reception, The Vasa Museum 19.30–21.30 Sponsored by Insmed Inc.
Friday August 8, 2003 Session 2: Multifunctional Role of IGFBPs 08.30–11.50 Chairs:
Victor Han, Canada Zee Upton, Australia
Invited Speakers: 08.30–09.15 Josef Silha, University of Manitoba, Canada S4 Perturbations in glucose metabolism in IGFBP transgenic mice 09.15–10.00 Subburaman Mohan, Loma Linda University, California, USA S5 Multifunctional role of IGFBPs in bone 10.00–10.30 Refreshment break
195
196
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Selected Presentations from Submitted Abstracts: 10.30–10.50 Daniela Kiepe, University Children’s Hospital, Heidelberg, Germany OR1 IGF-I stimulates cell proliferation and induces IGFBP-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes by use of distinct signaling pathways 10.50–11.10 Jens-Gerd Scharf, Georg-August-Universita¨t, Go¨ttingen, Germany OR2 Oxygen-dependent modulation of biosynthesis of IGF binding proteins in primary cultures of rat hepatocytes 11.10–11.30 Sue Firth, Kolling Institute of Medical Research, St Leonards, Australia OR3 The role of IGFBP-5 ternary complexes in IGF-I bioavailability 11.30–11.50 Leon Bach, University of Melbourne, Australia OR4 Three-dimensional structure of the C-domain of IGFBP-6 in solution using nuclear magnetic resonance (NMR) Session 3: Poster Session 11.50–14.30 Lunch will be served during the poster session Session 4: Regulation of IGFBP Proteolysis 14.30–15.55 Chairs:
Rob Baxter, Australia Peter Bang, Sweden
Invited Speakers: 14.30–15.15 John Fowlkes, University of Arkansas for Medical Sciences, USA S6 Insulin-like growth factor binding protein proteolysis: 2003 and beyond Selected Presentations from Submitted Abstracts: 15.15–15.35 Simon Pedersen, University of Aarhus, Denmark OR5 Disulfide structure of the proform of eosinophil major basic protein; mechanistic implications for the PAPP-A/ProMBP complex formation 15.35–15.55 Sandra Oesterreicher, University of Hamburg, Germany OR6 Characterization of an IGF-II-binding protein complex with proteolytic activity isolated from human plasma Dinner and Cruise, Lake Ma¨laren 19.00–23.00 Sponsored by Pharmacia Corporation, Sweden
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Saturday August 9, 2003 Session 5: IGFBPs and Cell Signaling 08.30–11.40 Chairs:
Pinchas Cohen, USA Claire Perks, UK
Invited Speakers: 08.30–09.00 Jean-Marc Ricort, INSERM, Hoˆpital Saint-Antoine, Paris, France S7 IGFBP signaling pathways activated independently of IGF-binding 09.00–09.30 Rebecca Taub, University of Pennsylvania School of Medicine, USA S8 IGFBP-1 and the adaptive response to liver injury 09.30–10.00 Laura Maile, University of North Carolina, USA S9 IGFBPs and IGF-I receptor signaling 10.00–10.30 Refreshment break Selected Presentations from Submitted Abstracts: 10.30–11.00 Zee Upton, Queensland University of Technology, Australia OR7 Novel IGF:IGFBP complexes for applications in tissue repair and regeneration 11.00–11.20 Anna Spagnoli, Vanderbilt University Medical Center, USA OR8 Interplay of insulin-like growth factor binding protein-3 and TGFb in mesenchymal chondroprogenitor stem cells 11.20–11.40 S Mishra, University of Manitoba, Canada OR9 Interaction of IGFBP-3 with autocrine motility factor on the cell surface of T-47D breast cancer cells Reception, Stockholm Town Hall 13.00–15.00 Sponsored by Stockholm City
Sunday August 10, 2003 Session 6: IGFBPs in Programmed Cell Death 08.30–10.45 Chairs: Invited Speaker: 08.30–0915
Moira Lewitt, Sweden Jeff Holly, UK Boris Zhivotovsky, Karolinska Institutet, Sweden S10 Gene Regulation of Programmed Cell Death
197
198
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Selected Presentations from Submitted Abstracts: 09.15–09.45 Matthew Rechler, National Institutes of Health, Bethesda, USA OR10 IGFBP-3-induced apoptosis in PC-3 human prostate cancer cells is initiated by FADD-dependent activation of caspase 8 09.45–10.05 Maaria Ikonen, University of California, Los Angeles, USA OR11 The Alzheimer’s survival peptide humanin binds IGFBP-3 and antagonizes its pro-apoptotic functions 10.05–10.25 Alison Butt, Kolling Institute of Medical Research, St Leonards, Australia OR12 Enhancement of tumour necrosis factor-mediated growth inhibition by IGFBP-5 but not IGFBP-3 in human breast cancer cells 10.25–10.45 Claire Perks, Bristol Royal Infirmary, UK OR13 Disruption of cholesterol stabilised membrane complexes modulates the actions of IGFBP-3 on apoptosis in HS578T human breast cancer cells
Refreshment Break 10.45–11.15
Session 7: The Yin and Yang of IGFBP-3 Action 11.15–12.30 Chair:
Derek LeRoith
Discussants:
Rob Baxter, Kolling Institute of Medical Research, Australia Pinchas Cohen, University of California, Los Angeles, USA
Lunch 12.30–13.30
Session 8: IGFBPs in Clinical Therapeutics 13.30–15.30 Chairs:
Subburaman Mohan, USA Kerstin Brismar, Sweden
Invited Speakers: 13.30–14.00 Jeff Holly, Bristol Royal Infirmary, UK S11 Use of IGFBPs in Cancer Therapy 14.00–14.30 Cecilia Camacho-Hu¨bner, St Bartholomew’s and Royal London School of Medicine and Dentistry, UK S12 Therapeutic indications for IGF-I/IGFBP-3 complex
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
199
Selected Presentations from Submitted Abstracts: 14.30–14.50 Heather-Marie Wilson, Fred Hutchinson Cancer Research Center, Seattle, USA OR14 IGFBP-3 levels are increased in early-stage myelodysplastic syndrome and may contribute to disease pathophysiology by altering apoptotic and proliferative responses in hemopoietic cells 14.50–15.10 Nadine Wilczak, Academisch Ziekenhuis Groningen, The Netherlands OR15 Upregulation of insulin-like growth factor binding proteins-1 and -6 in oligodendrocytes in chronic multiple sclerosis lesions 15.10–15.30 Stephanie Edmondson, Murdoch Children’s Research Institute, Australia OR16 IGFBP-3 localises to and modulates proliferative epidermal keratinocytes in vivo Refreshment Break 15.30–15.45 Session 9: Where Have We Been, and Where Are We Going? 15.45–16.15 Chair:
Kerstin Hall
Invited Speaker:
Ray Hintz, Stanford University, California, USA S13
Index of posters / Growth Hormone & IGF Research 13 (2003) 193–202
201
Index of Posters P1
IGFBP-1 response to nutritional deprivation is impaired in type 2 diabetes mellitus Kerstin Brismar, Kerstin Hall, Moira S. Lewitt
P2
Further evidence for insulin-like growth factor binding protein-1 (IGFBP-1) as a biomarker of hepatic insulin sensitivity A.H. Heald, J.K. Cruickshank, A. Vyas, J. Patel, K. Siddals, A. Rudenski, S. Anderson, J.M. Gibson
P3
A randomised controlled intervention study to examine direct modulation of the IGF-system by diet A.H. Heald, C. Golding, R. Sharma, K. Siddals, S. Anderson, J.E. Cade, J.M. Gibson
P4
Forearm skin microvascular reactivity, IGF-I, and IGFBP-1 in healthy subjects with and without heredity for type 2 diabetes ¨ stensson, K. Brismar G. Jo¨rneskog, J. Kuhl, M. Kalani, S. Efendic, C.-G. O
P5
Relationship between IGFBP-2 and risk factors for macrovascular disease in type 2 diabetes K. Kaushal, S. Anderson, A. Rudenski, A.H. Heald, J.M. Gibson
P6
Marked heterogeneity in growth hormone doses required to normalize IGF-I in IGF deficient children with or without GH deficiency: potential predictive role of baseline IGFBP-3 George M. Bright, Pinchas Cohen, Bob An, Ron Rosenfeld
P7
Appropriate increase in IGF-I and IGFBP3 during GH treatment in HIV positive subjects with wasting and lipohypertrophy Joseph M. Gertner, Daena Bock, Norma Muurahainen, Fanny O’Brien, Elisabeth Svanberg
P8
Effects of growth hormone on serum levels and hepatic expression of IGFBP-6 in humans Henrik von Horn, Tomas Ekstro¨m, Kerstin Hall, Michael Tally
P9
Changes in seminal plasma IGFI, IGFII, and IGFBP-3 with ageing Li Fu, Aye Nyein Tint, Andrew Hoffman, Arief T. Bongso, K.-O. Lee
P10 Expression of IGF-I, IGF-I receptor, and IGF-binding proteins in human synovial cells of patients with rheumatoid arthritis Tomoko Matsumoto, Toshiyuki Tsurumoto, Hiroyuki Shindo P11 Insulin-like growth factor binding protein-4 and receptors for IGF-I and insulin are expressed in human endothelium Simona I. Chisalita, Marloes Dekker-Nitert, Hans Arnqvist P12 IGFBP-4 in children with acute lymphoblastic leukemia Heike Wex, Do¨rte Ahrens, Bianka Hohmann, Uwe Mittler, Peter Vorwerk P13 Population migration profoundly influences the IGF-system in subjects originally from Gujarat, India A.H. Heald, J.K. Cruickshank, A. Vyas, J. Patel, K. Siddals, S. Anderson, J.M. Gibson P14 Markedly different effects of hormone replacement regimens on the IGF-system according to progestin formulation A.H. Heald, K. Kaushal, S. Anderson, A.P. Yates, P. Durrington, P. Selby, J.M. Gibson P15 Expression and regulation of the insulin-like growth factor axis components in rat liver myofibroblasts Ruslan Novosyadlyy, Kyrylo Tron, Jozsef Dudas, Giuliano Ramadori, Jens-Gerd Scharf P16 IGFBP-3 FRAGMENTS IN PLASMA OF A CHILD WITH AN AUTOIMMUNE DISORDER Victoria Schebek-Fu¨rstenberg, Dirk E. Mu¨ller-Wiefel, Werner F. Blum, Thomas Braulke, Bernd Ku¨bler P17 Quantification of serum IGFBP-3 proteolysis in patients with colorectal cancer A.G. Renehan, K Khosravi, A. Diamandi, S.T. O’Dwyer, S.M. Shalet
202
Index of posters / Growth Hormone & IGF Research 13 (2003) 193–202
P18 Gender specific patterns of IGFBP-3 protease activity in mouse thyroid Jing Wang, Inga-Lena Wivall-Helleryd, Jacob Gru¨nler, Moira S. Lewitt P19 UV-induced apoptosis of human keratinocytes is associated with IGFBP-3 proteolysis Susan Thumiger, Tim Adams, George Werther, Christopher Wraight, Stephanie Edmondson P20 Site directed mutagenesis to alter hIGFBP-2 cell surface association and proteolytic processing D.G. Cossens, S.I. Ymer, E. Andaloro, B. Schutt, A. Hoeflich, D.D. Mikol, E. Feldman, L.A. Bach, G.A. Werther, V.C. Russo P21 Analysis of the cleavage of IGFBP-4 and -5 chimeras by PAPP-A; differential effect of IGF Michael T. Overgaard, Vivien Rodacker, Lisbeth S. Laursen, Claus Oxvig P22 The divergent effect of insulin-like growth factor binding protein (IGFBP)-1 on IGF-induced steroidogenesis in bovine adrenocortical cells is not due to its phosphorylation status Christian Fottner, Gerald Spo¨ttl, Dieter Engelhardt, Matthias M. Weber P23 Kidney growth in normal and diabetic mice is not affected by hIGFBP-1 administration Vesna Cingel-Ristiæ, Bieke F. Schrijvers, Arle`ne K. van Vliet, Ruth Rasch, Stenvert L.S. Drop, Allan Flyvbjerg P24 Role of endogenous IGFBP-1 in the survival of INS-1 pancreatic beta cells Moira S. Lewitt, Jing Wang, A. Majid P25 IGF:IGFBP:vitronectin (VN) complexes stimulate cell migration and protein synthesis in HaCAT human keratinocytes Carolyn E. Hyde, Damien Harkin, Zee Upton P26 Manipulation of lipid rafts has differential effects on IGF-I and IGFBP-3-induced proliferation in the relatively normal MCF10A breast epithelial cells Martin A. Clark, Zoe E. Winters, Jeff M.P. Holly, Claire M. Perks P27 IGFBP-3 mediates endothelial cell survival and apoptosis, likely via the ceramide signaling pathway Riccarda Granata, Marzia De Petrini, Daniela Atragene, Marina Taliano, Fabio Broglio, Giulia Somenzi, Riccardo Ghidoni, Ezio Ghigo P28 Differential effects of IGFBP-3 on apoptosis of breast epithelial cells according to apoptotic trigger C. Burrows, L.J. Shiry, J.M.P. Holly, C.M. Perks P29 Impact of c-myb on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human chronic myelogenous leukemia cells Dae-Yeol Lee, Ho Keun Yi, Sun Yong Kim, Pyoung Han Hwang
Abstracts of the 5th International Workshop on IGF-Binding Proteins August 7–10, 2003 Karolinska Institutet Stockholm, Sweden Scientific Organising Committee Moira Lewitt, Chair (Sweden) Kerstin Hall, Co-Chair (Sweden) Kerstin Brismar, Co-Chair (Sweden) Peter Bang (Sweden) Ross Clark (New Zealand) David Clemmons (USA) Pinchas Cohen (USA) Allan Flyvbjerg (Denmark) Linda Giudice (USA) Yukihiro Hasegawa (Japan) Janet Martin (Australia) Philippe Monget (France) Liam Murphy (Canada) Claire Perks (UK) Zee Upton (Australia)
doi:10.1016/S1096-6374(03)00037-6
Major Sponsor Novo Nordisk Foundation Other Sponsors The Wenner-Gren Foundation Insmed Inc. Diagnostic Systems Laboratories, Inc. Biovitrum AB Pharmacia Corporation, Sweden Novo Nordisk Scandinavia AB Glaxo SmithKline, Sweden
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Meeting Plan Thursday August 7, 2003 Registration 13.00–17.30 Session 1: IGFBPs and the Somatomedin Hypothesis 2003 15.40–17.30 Chairs: 15.40–16.00
Kerstin Brismar, Kerstin Hall and Moira Lewitt, Sweden Introduction
Invited Speakers: 16.00–16.30 Victor Han, The University of Western Ontario, Canada S1 Regional expression of the IGF system during development: Evidence for autocrine/ paracrine actions of IGFBPs 16.30–17.00 Jan Frystyk, Aarhus University Hospital, Denmark S2 What are ‘‘free IGFs’’? 17.00–17.30 Derek LeRoith, NIH, Bethesda, USA S3 What is the role of circulating IGF-I? Reception, The Vasa Museum 19.30–21.30 Sponsored by Insmed Inc.
Friday August 8, 2003 Session 2: Multifunctional Role of IGFBPs 08.30–11.50 Chairs:
Victor Han, Canada Zee Upton, Australia
Invited Speakers: 08.30–09.15 Josef Silha, University of Manitoba, Canada S4 Perturbations in glucose metabolism in IGFBP transgenic mice 09.15–10.00 Subburaman Mohan, Loma Linda University, California, USA S5 Multifunctional role of IGFBPs in bone 10.00–10.30 Refreshment break
195
196
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Selected Presentations from Submitted Abstracts: 10.30–10.50 Daniela Kiepe, University Children’s Hospital, Heidelberg, Germany OR1 IGF-I stimulates cell proliferation and induces IGFBP-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes by use of distinct signaling pathways 10.50–11.10 Jens-Gerd Scharf, Georg-August-Universita¨t, Go¨ttingen, Germany OR2 Oxygen-dependent modulation of biosynthesis of IGF binding proteins in primary cultures of rat hepatocytes 11.10–11.30 Sue Firth, Kolling Institute of Medical Research, St Leonards, Australia OR3 The role of IGFBP-5 ternary complexes in IGF-I bioavailability 11.30–11.50 Leon Bach, University of Melbourne, Australia OR4 Three-dimensional structure of the C-domain of IGFBP-6 in solution using nuclear magnetic resonance (NMR) Session 3: Poster Session 11.50–14.30 Lunch will be served during the poster session Session 4: Regulation of IGFBP Proteolysis 14.30–15.55 Chairs:
Rob Baxter, Australia Peter Bang, Sweden
Invited Speakers: 14.30–15.15 John Fowlkes, University of Arkansas for Medical Sciences, USA S6 Insulin-like growth factor binding protein proteolysis: 2003 and beyond Selected Presentations from Submitted Abstracts: 15.15–15.35 Simon Pedersen, University of Aarhus, Denmark OR5 Disulfide structure of the proform of eosinophil major basic protein; mechanistic implications for the PAPP-A/ProMBP complex formation 15.35–15.55 Sandra Oesterreicher, University of Hamburg, Germany OR6 Characterization of an IGF-II-binding protein complex with proteolytic activity isolated from human plasma Dinner and Cruise, Lake Ma¨laren 19.00–23.00 Sponsored by Pharmacia Corporation, Sweden
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Saturday August 9, 2003 Session 5: IGFBPs and Cell Signaling 08.30–11.40 Chairs:
Pinchas Cohen, USA Claire Perks, UK
Invited Speakers: 08.30–09.00 Jean-Marc Ricort, INSERM, Hoˆpital Saint-Antoine, Paris, France S7 IGFBP signaling pathways activated independently of IGF-binding 09.00–09.30 Rebecca Taub, University of Pennsylvania School of Medicine, USA S8 IGFBP-1 and the adaptive response to liver injury 09.30–10.00 Laura Maile, University of North Carolina, USA S9 IGFBPs and IGF-I receptor signaling 10.00–10.30 Refreshment break Selected Presentations from Submitted Abstracts: 10.30–11.00 Zee Upton, Queensland University of Technology, Australia OR7 Novel IGF:IGFBP complexes for applications in tissue repair and regeneration 11.00–11.20 Anna Spagnoli, Vanderbilt University Medical Center, USA OR8 Interplay of insulin-like growth factor binding protein-3 and TGFb in mesenchymal chondroprogenitor stem cells 11.20–11.40 S Mishra, University of Manitoba, Canada OR9 Interaction of IGFBP-3 with autocrine motility factor on the cell surface of T-47D breast cancer cells Reception, Stockholm Town Hall 13.00–15.00 Sponsored by Stockholm City
Sunday August 10, 2003 Session 6: IGFBPs in Programmed Cell Death 08.30–10.45 Chairs: Invited Speaker: 08.30–0915
Moira Lewitt, Sweden Jeff Holly, UK Boris Zhivotovsky, Karolinska Institutet, Sweden S10 Gene Regulation of Programmed Cell Death
197
198
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
Selected Presentations from Submitted Abstracts: 09.15–09.45 Matthew Rechler, National Institutes of Health, Bethesda, USA OR10 IGFBP-3-induced apoptosis in PC-3 human prostate cancer cells is initiated by FADD-dependent activation of caspase 8 09.45–10.05 Maaria Ikonen, University of California, Los Angeles, USA OR11 The Alzheimer’s survival peptide humanin binds IGFBP-3 and antagonizes its pro-apoptotic functions 10.05–10.25 Alison Butt, Kolling Institute of Medical Research, St Leonards, Australia OR12 Enhancement of tumour necrosis factor-mediated growth inhibition by IGFBP-5 but not IGFBP-3 in human breast cancer cells 10.25–10.45 Claire Perks, Bristol Royal Infirmary, UK OR13 Disruption of cholesterol stabilised membrane complexes modulates the actions of IGFBP-3 on apoptosis in HS578T human breast cancer cells
Refreshment Break 10.45–11.15
Session 7: The Yin and Yang of IGFBP-3 Action 11.15–12.30 Chair:
Derek LeRoith
Discussants:
Rob Baxter, Kolling Institute of Medical Research, Australia Pinchas Cohen, University of California, Los Angeles, USA
Lunch 12.30–13.30
Session 8: IGFBPs in Clinical Therapeutics 13.30–15.30 Chairs:
Subburaman Mohan, USA Kerstin Brismar, Sweden
Invited Speakers: 13.30–14.00 Jeff Holly, Bristol Royal Infirmary, UK S11 Use of IGFBPs in Cancer Therapy 14.00–14.30 Cecilia Camacho-Hu¨bner, St Bartholomew’s and Royal London School of Medicine and Dentistry, UK S12 Therapeutic indications for IGF-I/IGFBP-3 complex
Meeting plan / Growth Hormone & IGF Research 13 (2003) 193–202
199
Selected Presentations from Submitted Abstracts: 14.30–14.50 Heather-Marie Wilson, Fred Hutchinson Cancer Research Center, Seattle, USA OR14 IGFBP-3 levels are increased in early-stage myelodysplastic syndrome and may contribute to disease pathophysiology by altering apoptotic and proliferative responses in hemopoietic cells 14.50–15.10 Nadine Wilczak, Academisch Ziekenhuis Groningen, The Netherlands OR15 Upregulation of insulin-like growth factor binding proteins-1 and -6 in oligodendrocytes in chronic multiple sclerosis lesions 15.10–15.30 Stephanie Edmondson, Murdoch Children’s Research Institute, Australia OR16 IGFBP-3 localises to and modulates proliferative epidermal keratinocytes in vivo Refreshment Break 15.30–15.45 Session 9: Where Have We Been, and Where Are We Going? 15.45–16.15 Chair:
Kerstin Hall
Invited Speaker:
Ray Hintz, Stanford University, California, USA S13
Index of posters / Growth Hormone & IGF Research 13 (2003) 193–202
201
Index of Posters P1
IGFBP-1 response to nutritional deprivation is impaired in type 2 diabetes mellitus Kerstin Brismar, Kerstin Hall, Moira S. Lewitt
P2
Further evidence for insulin-like growth factor binding protein-1 (IGFBP-1) as a biomarker of hepatic insulin sensitivity A.H. Heald, J.K. Cruickshank, A. Vyas, J. Patel, K. Siddals, A. Rudenski, S. Anderson, J.M. Gibson
P3
A randomised controlled intervention study to examine direct modulation of the IGF-system by diet A.H. Heald, C. Golding, R. Sharma, K. Siddals, S. Anderson, J.E. Cade, J.M. Gibson
P4
Forearm skin microvascular reactivity, IGF-I, and IGFBP-1 in healthy subjects with and without heredity for type 2 diabetes ¨ stensson, K. Brismar G. Jo¨rneskog, J. Kuhl, M. Kalani, S. Efendic, C.-G. O
P5
Relationship between IGFBP-2 and risk factors for macrovascular disease in type 2 diabetes K. Kaushal, S. Anderson, A. Rudenski, A.H. Heald, J.M. Gibson
P6
Marked heterogeneity in growth hormone doses required to normalize IGF-I in IGF deficient children with or without GH deficiency: potential predictive role of baseline IGFBP-3 George M. Bright, Pinchas Cohen, Bob An, Ron Rosenfeld
P7
Appropriate increase in IGF-I and IGFBP3 during GH treatment in HIV positive subjects with wasting and lipohypertrophy Joseph M. Gertner, Daena Bock, Norma Muurahainen, Fanny O’Brien, Elisabeth Svanberg
P8
Effects of growth hormone on serum levels and hepatic expression of IGFBP-6 in humans Henrik von Horn, Tomas Ekstro¨m, Kerstin Hall, Michael Tally
P9
Changes in seminal plasma IGFI, IGFII, and IGFBP-3 with ageing Li Fu, Aye Nyein Tint, Andrew Hoffman, Arief T. Bongso, K.-O. Lee
P10 Expression of IGF-I, IGF-I receptor, and IGF-binding proteins in human synovial cells of patients with rheumatoid arthritis Tomoko Matsumoto, Toshiyuki Tsurumoto, Hiroyuki Shindo P11 Insulin-like growth factor binding protein-4 and receptors for IGF-I and insulin are expressed in human endothelium Simona I. Chisalita, Marloes Dekker-Nitert, Hans Arnqvist P12 IGFBP-4 in children with acute lymphoblastic leukemia Heike Wex, Do¨rte Ahrens, Bianka Hohmann, Uwe Mittler, Peter Vorwerk P13 Population migration profoundly influences the IGF-system in subjects originally from Gujarat, India A.H. Heald, J.K. Cruickshank, A. Vyas, J. Patel, K. Siddals, S. Anderson, J.M. Gibson P14 Markedly different effects of hormone replacement regimens on the IGF-system according to progestin formulation A.H. Heald, K. Kaushal, S. Anderson, A.P. Yates, P. Durrington, P. Selby, J.M. Gibson P15 Expression and regulation of the insulin-like growth factor axis components in rat liver myofibroblasts Ruslan Novosyadlyy, Kyrylo Tron, Jozsef Dudas, Giuliano Ramadori, Jens-Gerd Scharf P16 IGFBP-3 FRAGMENTS IN PLASMA OF A CHILD WITH AN AUTOIMMUNE DISORDER Victoria Schebek-Fu¨rstenberg, Dirk E. Mu¨ller-Wiefel, Werner F. Blum, Thomas Braulke, Bernd Ku¨bler P17 Quantification of serum IGFBP-3 proteolysis in patients with colorectal cancer A.G. Renehan, K Khosravi, A. Diamandi, S.T. O’Dwyer, S.M. Shalet
202
Index of posters / Growth Hormone & IGF Research 13 (2003) 193–202
P18 Gender specific patterns of IGFBP-3 protease activity in mouse thyroid Jing Wang, Inga-Lena Wivall-Helleryd, Jacob Gru¨nler, Moira S. Lewitt P19 UV-induced apoptosis of human keratinocytes is associated with IGFBP-3 proteolysis Susan Thumiger, Tim Adams, George Werther, Christopher Wraight, Stephanie Edmondson P20 Site directed mutagenesis to alter hIGFBP-2 cell surface association and proteolytic processing D.G. Cossens, S.I. Ymer, E. Andaloro, B. Schutt, A. Hoeflich, D.D. Mikol, E. Feldman, L.A. Bach, G.A. Werther, V.C. Russo P21 Analysis of the cleavage of IGFBP-4 and -5 chimeras by PAPP-A; differential effect of IGF Michael T. Overgaard, Vivien Rodacker, Lisbeth S. Laursen, Claus Oxvig P22 The divergent effect of insulin-like growth factor binding protein (IGFBP)-1 on IGF-induced steroidogenesis in bovine adrenocortical cells is not due to its phosphorylation status Christian Fottner, Gerald Spo¨ttl, Dieter Engelhardt, Matthias M. Weber P23 Kidney growth in normal and diabetic mice is not affected by hIGFBP-1 administration Vesna Cingel-Ristiæ, Bieke F. Schrijvers, Arle`ne K. van Vliet, Ruth Rasch, Stenvert L.S. Drop, Allan Flyvbjerg P24 Role of endogenous IGFBP-1 in the survival of INS-1 pancreatic beta cells Moira S. Lewitt, Jing Wang, A. Majid P25 IGF:IGFBP:vitronectin (VN) complexes stimulate cell migration and protein synthesis in HaCAT human keratinocytes Carolyn E. Hyde, Damien Harkin, Zee Upton P26 Manipulation of lipid rafts has differential effects on IGF-I and IGFBP-3-induced proliferation in the relatively normal MCF10A breast epithelial cells Martin A. Clark, Zoe E. Winters, Jeff M.P. Holly, Claire M. Perks P27 IGFBP-3 mediates endothelial cell survival and apoptosis, likely via the ceramide signaling pathway Riccarda Granata, Marzia De Petrini, Daniela Atragene, Marina Taliano, Fabio Broglio, Giulia Somenzi, Riccardo Ghidoni, Ezio Ghigo P28 Differential effects of IGFBP-3 on apoptosis of breast epithelial cells according to apoptotic trigger C. Burrows, L.J. Shiry, J.M.P. Holly, C.M. Perks P29 Impact of c-myb on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human chronic myelogenous leukemia cells Dae-Yeol Lee, Ho Keun Yi, Sun Yong Kim, Pyoung Han Hwang